Phase II study of fosaprepitant + 5HT3 receptor antagonist + dexamethasone in patients with germ cell tumors undergoing 5-day cisplatin-based chemotherapy: a Hoosier Cancer Research Network study

Purpose A phase III study adding aprepitant to a 5HT3 receptor antagonist (5HT3-RA) plus dexamethasone in germ cell tumor (GCT) patients treated with 5-day cisplatin combination chemotherapy demonstrated a significant improvement in complete response (CR) (J Clin Onc 30:3998-4003, 2012). Fosaprepita...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Supportive care in cancer 2016-07, Vol.24 (7), p.2837-2842
Hauptverfasser:	Adra, Nabil, Albany, Costantine, Brames, Mary J., Case-Eads, Somer, Johnson, Cynthia S., Liu, Ziyue, Fausel, Christopher A., Breen, Timothy, Hanna, Nasser H., Hauke, Ralph J., Picus, Joel, Einhorn, Lawrence H.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Aged Antineoplastic agents Cancer Cancer research Care and treatment Chemotherapy Cisplatin - administration & dosage Cisplatin - pharmacology Cisplatin - therapeutic use Clinical trials Comparative analysis Dexamethasone Dexamethasone - administration & dosage Dexamethasone - pharmacology Dexamethasone - therapeutic use Drug Therapy, Combination Female Gastrointestinal agents Humans Male Medicine Medicine & Public Health Middle Aged Morpholines - administration & dosage Morpholines - pharmacology Morpholines - therapeutic use Nausea Neoplasms, Germ Cell and Embryonal - drug therapy Neoplasms, Germ Cell and Embryonal - pathology Nursing Nursing Research Oncology Original Article Pain Medicine Rehabilitation Medicine Serotonin 5-HT3 Receptor Antagonists - administration & dosage Serotonin 5-HT3 Receptor Antagonists - pharmacology Serotonin 5-HT3 Receptor Antagonists - therapeutic use Studies Testicular cancer Tumors Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!